Skip to main content

Clene Inc.

corporate_fare Company Profile

Clene Inc.

CLNN·NASDAQ·Life Sciences·CIK 0001822791

We are a clinical-stage pharmaceutical company focused on discovering, developing, and selling new clean-surfaced nanotechnology ("CSN®") therapeutics. These CSN® therapeutics are made from transition element atoms that, when formed into nanocrystals, have unusually high and unique catalytic activities not found in the same elements in their bulk form. These activities support beneficial metabolic and energetic cellular reactions in diseased, stressed, and damaged cells. We believe our patented technology allows us to develop a wide range of CSN therapeutics for various diseases impacting human health. We developed an electro-crystal-chemistry drug development platform using advances in nanotechnology, plasma and quantum physics, materials science, and biochemistry. This platform creates nanocrystals with faceted structures and surfaces free of chemical modifications often found with other production methods, which can leave potentially toxic residues. Our method produces stable, non-toxic, and highly catalytic nanocrystals, overcoming a major challenge in using transition metal catalytic activity for therapy. Our clean-surfaced nanocrystals show catalytic activities many times higher than other commercially available nanoparticles we have evaluated. Our development and clinical efforts aim to transform the treatment of neurodegenerative diseases by restoring and protecting neuronal health and function. Our nanotherapeutics target cellular energy problems common to many diseases. We are currently focused on addressing significant unmet medical needs in central nervous system disorders, including amyotrophic lateral sclerosis ("ALS"), multiple sclerosis ("MS"), and Parkinson's disease ("PD"). Our drug development approach is innovation-focused and scientifically driven.

Clene Inc. (NASDAQ:CLNN) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 42 items for CLNN at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-04, rated 8/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 13 rated 8 or above. Recent SEC coverage for CLNN spans 10-Q, 424B5, 8-K, 144.

Recent high-impact activity:

  • Clene 10-Q: $3.9M Q3 'Net Income' Is Non-Cash; Cash Covers Only to Mid-Q1 2027
  • Clene Swings to $3.92M Third-Quarter Net Income
  • Clene Files FDA NDA for ALS Drug CNM-Au8 Under Accelerated Approval Pathway
  • Clene Prices $4M Registered Direct Offering at $3.28; Insiders Commit $2.1M
  • Clene Prices $4M Registered Direct Offering at $3.28/Share

Financial Snapshot

Fiscal year ended December 31, 2025
Revenue
$200K
Net Income
-$26.17M
Op. Cash Flow
-$18.55M
Free Cash Flow
-$18.59M
Gross Profit
$157K
Operating Income
-$23.08M
Cash & Equivalents
$5.19M
Total Debt
$17.79M
Debt / Equity
-1.01×
Net Margin
-130.87×
Shares Outstanding
10.85M sh
Source: 10-K · filed 2026-03-17 · accession 0001437749-26-008502

Short Interest & Short Volume

5.06 days to cover

FINRA reported short interest of 416,980 shares in CLNN as of the October 30, 2026 settlement, a 1.9% decrease from the prior period — about 5.1 days to cover at its recent average daily volume. On November 20, 2026, 44.7% of CLNN volume reported to FINRA trade-reporting facilities was marked short.

Short interest (bi-monthly positions)416,980 shares as of October 30, 2026
Change vs prior period▼ 1.9%
Days to cover5.06 at avg daily volume of 82,334
Daily short volume (FINRA facilities)44.7% of 68,548 shares on November 20, 2026
5-day average short volume39.7%

Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.

Dilution Risk

Low risk

Filing-implied dilution signals for CLNN, detected from its recent SEC filings · based on capital-structure filings through 2026-09-16.

1 recent capital raise

$4M Registered Direct Offering Priced · Insiders Commit $2.1M

A filing-implied signal, not a realized share count. How Wiseek tracks dilution →

Browse all tickers starting with C →
$3.59 +1.99% today
52-week range · as of 2026-11-04 $3.02 – $13.5
Market cap
$50.69M
Volume
144.1K (1.3× avg)
3-mo avg 107.7K
Live data · 2026-11-22 10:19 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed CLNN - Latest Insights

CLNN
Nov 04, 2026, 8:36 AM EST
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $3.77
Real-time Price: $3.59 info
Change: -$0.180 (-5%) info
Market Cap: $50.689M info
CLNN
Nov 04, 2026, 8:31 AM EST
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $3.77
Real-time Price: $3.59 info
Change: -$0.180 (-5%) info
Market Cap: $50.689M info
CLNN
Oct 19, 2026, 8:00 AM EDT
Source: Wiseek News
Importance Score:
8
Price at Filing: $3.16
Real-time Price: $3.59 info
Change: +$0.430 (+14%) info
Market Cap: $50.689M info
CLNN
Sep 16, 2026, 1:05 PM EDT
Filing Type: 424B5
Importance Score:
7
Price at Filing: $4.09
Real-time Price: $3.59 info
Change: -$0.500 (-12%) info
Market Cap: $50.689M info
CLNN
Sep 15, 2026, 9:00 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $3.09
Real-time Price: $3.59 info
Change: +$0.500 (+16%) info
Market Cap: $50.689M info
CLNN
Aug 14, 2026, 8:35 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $4.13
Real-time Price: $3.59 info
Change: -$0.540 (-13%) info
Market Cap: $50.689M info
CLNN
Aug 14, 2026, 8:01 AM EDT
Filing Type: 10-Q
Importance Score:
9
Price at Filing: $4.13
Real-time Price: $3.59 info
Change: -$0.540 (-13%) info
Market Cap: $50.689M info
CLNN
Aug 10, 2026, 8:07 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $5.28
Real-time Price: $3.59 info
Change: -$1.69 (-32%) info
Market Cap: $50.689M info
CLNN
May 22, 2026, 4:37 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $6.63
Real-time Price: $3.59 info
Change: -$3.04 (-46%) info
Market Cap: $50.689M info
CLNN
May 15, 2026, 3:15 AM EDT
Source: Wiseek News
Importance Score:
8
Price at Filing: $6.86
Real-time Price: $3.59 info
Change: -$3.27 (-48%) info
Market Cap: $50.689M info
CLNN
May 14, 2026, 8:02 AM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $6.50
Real-time Price: $3.59 info
Change: -$2.91 (-45%) info
Market Cap: $50.689M info
CLNN
May 14, 2026, 8:01 AM EDT
Source: Wiseek News
Importance Score:
8
Price at Filing: $6.50
Real-time Price: $3.59 info
Change: -$2.91 (-45%) info
Market Cap: $50.689M info
CLNN
May 14, 2026, 8:00 AM EDT
Source: GlobeNewswire
Importance Score:
9
Price at Filing: $6.50
Real-time Price: $3.59 info
Change: -$2.91 (-45%) info
Market Cap: $50.689M info
CLNN
May 14, 2026, 7:54 AM EDT
Filing Type: 10-Q
Importance Score:
9
Price at Filing: $6.50
Real-time Price: $3.59 info
Change: -$2.91 (-45%) info
Market Cap: $50.689M info
CLNN
May 11, 2026, 4:15 PM EDT
Filing Type: 144
Importance Score:
7
Price at Filing: $6.59
Real-time Price: $3.59 info
Change: -$3.00 (-46%) info
Market Cap: $50.689M info
CLNN
May 05, 2026, 5:53 PM EDT
Filing Type: 4
Importance Score:
7
Price at Filing: $6.82
Real-time Price: $3.59 info
Change: -$3.23 (-47%) info
Market Cap: $50.689M info
CLNN
May 05, 2026, 5:06 PM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $6.69
Real-time Price: $3.59 info
Change: -$3.10 (-46%) info
Market Cap: $50.689M info
CLNN
May 05, 2026, 5:03 PM EDT
Filing Type: 424B5
Importance Score:
8
Price at Filing: $6.69
Real-time Price: $3.59 info
Change: -$3.10 (-46%) info
Market Cap: $50.689M info
CLNN
May 05, 2026, 8:45 AM EDT
Source: Dow Jones Newswires
Importance Score:
8
Price at Filing: $7.27
Real-time Price: $3.59 info
Change: -$3.68 (-51%) info
Market Cap: $50.689M info
CLNN
May 04, 2026, 4:02 PM EDT
Filing Type: 144
Importance Score:
7
Price at Filing: $7.92
Real-time Price: $3.59 info
Change: -$4.33 (-55%) info
Market Cap: $50.689M info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets